North America Colorectal Cancer Diagnostics Market Outlook (2023–2028)
The North America colorectal cancer diagnostics market was valued at US$ 4,315.86 million in 2023 and is projected to reach US$ 6,621.26 million by 2028, growing at a CAGR of 8.9% during the forecast period. This growth is largely driven by technological advancements and frequent product innovations, which are enhancing the early detection and diagnosis of colorectal cancer (CRC) and related gastrointestinal (GI) conditions.
Market Drivers: Innovation and AI Integration
A significant catalyst for market expansion is the introduction of advanced diagnostic technologies, particularly those leveraging artificial intelligence (AI).
- In July 2022, US Digestive Health (USDH)—a leading GI practice network—commercialized AI-assisted colonoscopy screenings using the Genious Intelligent GI endoscopy module, marking the largest deployment of such technology in the U.S. This innovation improves real-time detection of hard-to-identify, potentially cancerous polyps, expanding access to enhanced screening across southeastern, southwestern, and central Pennsylvania.
- Similarly, in September 2020, Olympus Corporation launched ENDO-AID, an AI-powered platform featuring the CADe (Computer-Aided Detection) application, designed to identify suspicious colon lesions in real-time. Integrated with the EVIS X1 system, this platform offers a substantial leap forward in endoscopic diagnostics.
📚Download Full PDF Sample Copy of Market Report @
https://www.businessmarketinsights.com/sample/BMIRE00028834
These product launches underscore the market’s shift toward intelligent, data-driven diagnostics, which play a crucial role in improving early detection rates and reducing CRC-related mortality.
Epidemiology and Public Health Landscape
The market encompasses the U.S., Canada, and Mexico, with the U.S. dominating due to its high disease prevalence, robust healthcare infrastructure, and strong government backing for cancer research.
- In 2023, the American Society of Clinical Oncology (ASCO) estimated 153,020 new colorectal cancer cases in the U.S. alone, comprising 106,970 colon and 46,050 rectal cancer diagnoses.
- The lifetime risk of developing CRC stands at approximately 1 in 22 for men and 1 in 24 for women.
- Despite a higher risk among older adults, CRC incidence is rising among younger demographics, prompting changes in screening recommendations.
The US Preventive Services Task Force and the American Cancer Society have both lowered the recommended screening age from 50 to 45 years, reflecting this shifting risk profile. Additionally, with over 600,000 colon surgeries performed annually in the U.S., the demand for accurate diagnostics is substantial.
Improving Outcomes Through Early Detection
Early screening has contributed to a significant reduction in CRC mortality over the past two decades, primarily due to increased detection and more effective treatments. According to the American Cancer Society:
- The five-year survival rate is 91% for localized colon cancer and 90% for localized rectal cancer.
- Enhanced screening methods—such as high-sensitivity stool-based tests and visual examinations—are vital tools in decreasing cancer incidence and improving survival.
Supportive Research Ecosystem
Public and private sectors continue to invest in CRC research:
- The Colorectal Cancer Alliance, the largest global nonprofit in this domain, has been instrumental in patient advocacy and research funding.
- In 2020, US$ 1.1 million in grants were distributed to support cutting-edge CRC research, aiming to advance prevention, detection, and treatment methodologies.
North America Colorectal Cancer Diagnostics Strategic Insights
Strategic insights for the North America Colorectal Cancer Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
Market leaders and key company profiles
Bruker Corp
Clinical Genomics Technologies Pty Ltd
EDP Biotech Corp
Eiken Chemical Co., Ltd.
Epigenomics AG
F. Hoffmann-La Roche Ltd
Illumina Inc
Medtronic Plc
Quest Diagnostics Inc
Siemens Healthineers AG
North America Colorectal Cancer Diagnostics Regional Insights
The geographic scope of the North America Colorectal Cancer Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
North America Colorectal Cancer Diagnostics Market Segmentation
The North America colorectal cancer diagnostics market is segmented into modality, end user, and country.
Based on modality, the North America colorectal cancer diagnostics market is bifurcated into imaging tests and stool-based tests. In 2023, the imaging tests segment held a larger share of the North America colorectal cancer diagnostics market. The market for the imaging tests segment is further segmented into colonoscopy, CT colonography, flexible sigmoidoscopy, capsule endoscopy, and others. The market for the stool based tests segment is subsegmented into faecal immunochemical test (fit), guaiac-based faecal occult blood test (gFOBT), and stool DNA test.
Based on end user, the North America colorectal cancer diagnostics market is segmented into hospitals, diagnostic laboratories, cancer research institutes, and others. In 2023, the hospitals segment held the largest share of the North America colorectal cancer diagnostics market.
Based on country, the North America colorectal cancer diagnostics market is segmented into the US, Canada, and Mexico. In 2023, the US accounted for the largest share of the North America colorectal cancer diagnostics market.
Medtronic Plc; Illumina Inc; Clinical Genomics Technologies Pty Ltd; EDP Biotech Corp; Epigenomics AG; F. Hoffmann-La Roche Ltd; Quest Diagnostics Inc; Siemens Healthineers AG; Bruker Corp; and Eiken Chemical Co., Ltd. are among the leading companies operating in the North America colorectal cancer diagnostics market.
Can you see this our reports
Europe Halal Cosmetics Market – https://postyourarticle.com/europe-halal-cosmetics-market-trends-size-segment-and-growth-by-forecast-to-2030-3/
Europe Stevia Market – https://businessmarketins02.blogspot.com/2025/05/europe-stevia-market-trends-size.html
North America Functional Beverages Market – https://sites.google.com/view/businessmarketinsights233/home
North America Biodegradable Plastics Market – https://github.com/businessmarketinsights985/business-market-insights/issues/86
Europe Dental Market – https://www.linkedin.com/feed/update/urn:li:activity:7329122009718636569?utm_source=share&utm_medium=member_desktop&rcm=ACoAAFoU1YcBnRwRNJ26KRFoU-JXA3i-VZNmbCk
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Défense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
Author’s Bio
Akshay
Senior Market Research Expert at Business Market Insights
